Goodsell Amanda, Zhou Fengmin, Gupta Soumi, Singh Manmohan, Malyala Padma, Kazzaz Jina, Greer Catherine, Legg Harold, Tang Tony, Zur Megede January, Srivastava Ranjana, Barnett Susan W, Donnelly John J, Luciw Paul A, Polo John, O'Hagan Derek T, Vajdy Michael
Novartis Vaccines and Diagnostics, Inc., Emeryville, CA 94608, USA.
Immunology. 2008 Mar;123(3):378-89. doi: 10.1111/j.1365-2567.2007.02702.x. Epub 2007 Oct 17.
Vaccination strategies that can block or limit heterosexual human immunodeficiency virus (HIV) transmissions to local and systemic tissues are the goal of much research effort. Herein, in a mouse model, we aimed to determine whether the enhancement of antibody responses through mucosal and systemic immunizations, previously observed with protein-based vaccines, applies to immunizations with DNA- or RNA-based vectors. Intranasal (i.n.) followed by intramuscular (i.m.) immunizations (i.n./i.m.) with polylactide-coglycolide (PLG)-DNA microparticles encoding HIV-gag (PLG-DNA-gag) significantly enhanced serum antibody responses, compared with i.m., i.n. or i.m. followed by i.n. (i.m./i.n.) immunizations. Moreover, while i.n./i.m., i.n. or i.m./i.n. immunizations with PLG-DNA-gag resulted in genital tract antibody responses, i.m. immunizations alone failed to do so. Importantly, beta7-deficient mice developed local and systemic antibody responses following i.n./i.m. immunization, or immunization via any other route, similar to those of wild-type mice. To compare the DNA with an RNA delivery system, immunizations were performed with VEE/SIN-gag replicon particles, composed of Venezuelan equine encephalitis virus (VEE) replicon RNA and Sindbis surface structure (SIN). i.n./i.m., compared with any other immunizations, i.n./i.m. immunization with VEE/SIN-gag resulted in enhanced genital tract but not serum antibody responses. These data show for the first time that mucosal followed by systemic immunizations with gene delivery systems enhance B-cell responses independent of the mucosal homing receptors alpha4beta7 and alphaEbeta7.
能够阻断或限制异性间人类免疫缺陷病毒(HIV)向局部和全身组织传播的疫苗接种策略是众多研究工作的目标。在此,我们在小鼠模型中旨在确定,先前在基于蛋白质的疫苗中观察到的通过黏膜和全身免疫接种增强抗体反应的现象,是否适用于基于DNA或RNA的载体免疫接种。与肌肉注射(i.m.)、鼻内(i.n.)或先肌肉注射后鼻内(i.m./i.n.)免疫接种相比,用编码HIV - gag的聚乳酸 - 乙醇酸共聚物(PLG)-DNA微粒进行鼻内接种后再肌肉注射(i.n./i.m.),能显著增强血清抗体反应。此外,虽然用PLG - DNA - gag进行i.n./i.m.、i.n.或i.m./i.n.免疫接种会产生生殖道抗体反应,但单独的肌肉注射免疫接种却无法做到这一点。重要的是,β7缺陷小鼠在i.n./i.m.免疫接种或通过任何其他途径免疫接种后,产生的局部和全身抗体反应与野生型小鼠相似。为了将DNA与RNA递送系统进行比较,我们用由委内瑞拉马脑炎病毒(VEE)复制子RNA和辛德毕斯表面结构(SIN)组成的VEE/SIN - gag复制子颗粒进行免疫接种。与任何其他免疫接种相比,用VEE/SIN - gag进行i.n./i.m.免疫接种可增强生殖道抗体反应,但不会增强血清抗体反应。这些数据首次表明,用基因递送系统先进行黏膜免疫再进行全身免疫可增强B细胞反应,且与黏膜归巢受体α4β7和αEβ7无关。